IP Strategy is a Tricky Balancing Act for Pharmaceuticals

By Shai Jalfin
August 26, 2017

The 20 years of protection afforded by a patent is intended to promote innovation by allowing inventors a chance to recoup development costs and derive a profit from their efforts. However, in the pharmaceutical industry, the practical duration of protection is often substantially shorter since obtaining a patent is just one piece—albeit a critical one–of bringing a drug to market.

The other piece is U.S. Federal Drug Administration (FDA) approval. Unlike other products, all drugs and medicines are subject to a regulatory review period before they can be sold in the U.S. – and this process can eat up a sizeable portion of a drug’s patent term.

Timeline and cost of drug development

It takes an average of 10 to 15 years to develop a new drug – a process that’s not only time-consuming but expensive. The Tufts Center for the Study of Drug Development’s 2016 study found that the average R&D costs of a drug are close to $2.6 billion before FDA approval is received, and increase to nearly $2.9 billion with post-approval R&D.

By the time a new drug reaches the point where it’s ready for clinical testing on humans, a substantial investment has already been made. The pharmaceutical company has already seen the drug through an average of one to six years of compound discovery, synthesis, purification and often, limited animal testing. That’s why most pharmaceutical companies apply to patent their drugs during the research stage, before incurring the even-greater cost of human clinical trials.

FDA approval is required for the three stages of clinical trials, at the end of which — assuming the drug remains a viable product — a final New Drug Application (NDA) is filed with the FDA. Only after the NDA is approved can the company begin selling the medication. At this point, the average amount of time left on the patent is just 11.5 years.

Patent or trade secret?

While obtaining a patent is the most obvious way to protect a company’s IP, filling a patent application presents two major problems for the pharmaceutical industry:

  1. It starts the 20-year patent clock ticking (i.e. if the patent is granted, protection begins from the filing date).
  2. The discovery on which the new drug is based is exposed to competitors, since patent applications are public.

As a result, some companies are turning to trade secrets. According to the USPTO, trade secrets protect “information that can include a formula, pattern, compilation, program, device, method, technique or process…[which] give[s] an opportunity to obtain an economic advantage over competitors who do not know or use it.

The duration of a trade secret is indefinite, which makes it an attractive option given the length of the FDA approval process. In the U.S., a trade secret also offers a workaround for the recent restrictions on patents involving laws of nature. However, relying on trade secrets is risky – if exposed (whether on purpose or by accident), their protection evaporates.

Patent extensions

The proprietor of a pharmaceutical patent can apply to the USPTO for an extension of their patent term to make up for some of the time lost to the FDA approval process. However, the rules are a bit complicated and extensions rarely equal the patent time a company may feel it’s lost. Here are the provisions for getting an extension:

  1. The time under consideration for extension begins on the date the patent is issued.
  2. The maximum extension possible is equal to half of the FDA review period.
  3. The extension may not increase the effective patent term to more than 14 years.

To see how the rules are applied, let’s run through a typical pharma company’s development process:

Now, let’s apply the rules:

  1. The time under consideration is from 2007 (date of patent issue) to 2017 (end of regulatory review period). That’s 10 years.
  2. Company ABC can apply for a maximum extension of 5 years (half of the time under consideration).
  3. An extension of 5 years would raise the patent term to 12 years (because the effective patent life cycle was down to 7 years upon receipt of FDA approval). Since this is under 14 years, the law would permit the maximum extension.

Data exclusivity

The FDA may grant a bit more protection for the development of biologic drugs – i.e. genetically-engineered medications based on living organisms – via 12-year “data exclusivity” periods. These periods grant the pharma company exclusive rights to its clinical trial data so that the data cannot be used by a copy-cat competitor to quickly obtain a patent for a cheaper “biosimilar” drug.

Waiting to patent specific details

Another strategy is to apply for a drug’s patents in stages. A pharmaceutical company may decide at first to apply only for patent protection of the drug’s underlying compound before clinical trials to give as little away as possible about the product. Later, they can seek additional, more specific — and revealing — “method of use” and “formulation” patents as they get closer to final FDA approval.

A tricky balancing act

With so much money at stake and competition for profit so fierce, a pharmaceutical’s monetization roadmap needs a successful IP strategy for adequate protection. It’s a tricky balancing act between secrecy, security and timing.

The Author

Shai Jalfin

Shai Jalfin is the Senior Vice President of Morningside's patent division. Shai has helped numerous Fortune 500 clients and international patent firms streamline their formalities processes, reduce costs, and achieve more with their IP budgets. With over 10 years’ experience in foreign patent filing and EP validation, Shai has an extensive experience creating customized, cost-effective solutions for multinational filing.

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com. Read more.

Discuss this

There are currently 2 Comments comments. Join the discussion.

  1. angry dude August 26, 2017 9:16 am

    To teach the value of patents to those old PoSes in congress scotus cafc and elsewhere one needs to cancel (PTAB) all pharma patents in US (aren’t they all obvious ? – just different chemical compositions )
    The collapse of big pharma will follow next day..

    Then there won’t be any new miracle drugs for those old a$$holes so they’ll have to live with cheap overseas generics made by copycats

  2. Paul F. Morgan August 27, 2017 10:38 am

    35 U.S.C. §156 allows a patentee to obtains a patent term extension if the patent covers a product that has been subject to a regulatory review period before it can be marketed or used.

Post a Comment

Respectfully add to the discussion.

Name *
Email *
Website